Omeros Corporation reported a net loss from discontinued operations, net of tax, of $9.7 million, or $0.15 per share, for the third quarter of 2025, compared to net income from discontinued operations, net of tax, of $4.9 million, or $0.08 per share, in the same period of 2024. The decrease was mainly due to a non-cash remeasurement of the OMIDRIA contract royalty asset, reflecting changes in royalty estimates from Rayner. Interest expense was a credit of $13.4 million in the third quarter of 2025, compared to $4.1 million in the prior year quarter, primarily due to a non-cash remeasurement adjustment on the OMIDRIA royalty obligation to DRI. Interest and other income totaled $0.6 million, down from $2.3 million in the third quarter of 2024, mainly due to lower cash and investments available. Business developments during the quarter included completion of above-market financing in July, progress on the Novo Nordisk transaction expected to close before year-end, and anticipation of the FDA's decision on narsoplimab in TA-TMA.